Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rein Therapeutics (RNTX) EPS (Basic) (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed EPS (Basic) for 10 consecutive years, with -$0.21 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Basic) rose 22.22% to -$0.21 in Q3 2025 year-over-year; TTM through Sep 2025 was -$2.94, a 6.67% increase, with the full-year FY2024 number at -$3.51, down 2.63% from a year prior.
  • EPS (Basic) was -$0.21 for Q3 2025 at Rein Therapeutics, up from -$0.28 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of -$0.06 in Q2 2021 to a low of -$5.67 in Q4 2021.
  • A 5-year average of -$1.04 and a median of -$0.45 in 2024 define the central range for EPS (Basic).
  • Peak YoY movement for EPS (Basic): tumbled 4625.0% in 2021, then surged 82.36% in 2022.
  • Rein Therapeutics' EPS (Basic) stood at -$5.67 in 2021, then soared by 82.36% to -$1.0 in 2022, then tumbled by 57.0% to -$1.57 in 2023, then tumbled by 40.13% to -$2.2 in 2024, then soared by 90.45% to -$0.21 in 2025.
  • Per Business Quant, the three most recent readings for RNTX's EPS (Basic) are -$0.21 (Q3 2025), -$0.28 (Q2 2025), and -$0.25 (Q1 2025).